⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5116662 | 1.00 | — | — | |
| SCHEMBL25497611 | 1.00 | — | — | |
| SCHEMBL23964332 | 0.85 | OR51E2 (0.56) | — | |
| SCHEMBL14232888 | 0.81 | CRBN (0.56) | — | |
| SCHEMBL14232889 | 0.81 | CRBN (0.56) | — | |
| SCHEMBL17395320 | 0.81 | CRBN (0.56) | — | |
| SCHEMBL17395319 | 0.81 | CRBN (0.56) | — | |
| SCHEMBL14245467 | 0.81 | CRBN (0.56) | — | |
| SCHEMBL13058104 | 0.80 | GAA (0.48) | — | |
| SCHEMBL26886694 | 0.80 | OR51E2 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023214576-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | 中外製薬株式会社 | 2023-11-09 | — | — | WO | disclosed |
| US-11807617-B2 | Highly efficient synthesis of Z-macrocycles using stereoretentive, ruthenium-based metathesis catalysts | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230144534-A1 | CLEAVABLE TETRAZINE USED IN BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2023-05-11 | — | — | US | disclosed |
| WO-2022234853-A1 | CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS | 中外製薬株式会社 | 2022-11-10 | — | — | WO | disclosed |
| US-7329683-B2 | 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329683-B2 | 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329683-B2 | 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1474139-B1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | MERCK & CO INC (US) | 2007-11-21 | — | — | EP | disclosed |
| EP-1474139-B1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | MERCK & CO INC (US) | 2007-11-21 | — | — | EP | disclosed |
| EP-1474139-A4 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | MERCK & CO INC (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20050070720-A1 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | disclosed |
| EP-1474139-A2 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | Merck & Co., Inc. (US) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003065983-A2 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | MERCK & CO., INC. (US) | 2003-08-14 | — | — | WO | disclosed |
| US-5326850-A | Radiation crosslinking, high heat deflection temperature | BASF AKTIENGESELLSCHAFT (DE) | 1994-07-05 | — | — | US | disclosed |
| US-5266656-A | Blends of polyamides and polyamides with olefin bonds | BASF AKTIENGESELLSCHAFT (DE) | 1993-11-30 | — | — | US | disclosed |